PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer

Publication Date

2024

Content Type

Article

PubMed ID:

38513188

Additional Authors:

Additional authors and institutional affiliations

This document is currently not available here.

Share

COinS